ProMetic Life Sciences Stock Price, News & Analysis (TSE:PLI)

C$1.27 0.02 (1.60 %)
(As of 12/11/2017 06:19 AM ET)
Previous CloseC$1.25
Today's RangeC$1.25 - C$1.29
52-Week RangeC$1.12 - C$2.64
Volume776,376 shs
Average Volume994,542 shs
Market CapitalizationC$886.76 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34

About ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences logoPrometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolTSE:PLI
CUSIPN/A
Phone+1-450-7810115

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.17)
Net IncomeN/A
Net Margins-870.60%
Return on Equity-101.57%
Return on Assets-50.15%

Miscellaneous

EmployeesN/A
Outstanding Shares707,378,000

ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

When will ProMetic Life Sciences make its next earnings announcement?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for ProMetic Life Sciences.

Where is ProMetic Life Sciences' stock going? Where will ProMetic Life Sciences' stock price be in 2017?

6 brokers have issued 1 year price targets for ProMetic Life Sciences' shares. Their forecasts range from C$2.00 to C$4.50. On average, they expect ProMetic Life Sciences' share price to reach C$3.50 in the next year. View Analyst Ratings for ProMetic Life Sciences.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:

  • Simon Geoffrey Best, Independent Chairman of the Board (Age 60)
  • Pierre Laurin Ph.D., President, Chief Executive Officer, Non-Independent Director (Age 56)
  • Bruce Pritchard, Interim Chief Financial Officer, Chief Operating Officer
  • John Moran M.D., Chief Medical Officer, Director (Age 71)
  • Patrick Sartore, Chief Legal Officer and Corporate Secretary
  • Stefan Clulow, Non-Independent Director (Age 46)
  • Charles N. Kenworthy, Non-Independent Director (Age 58)
  • Bruce J. Wendel, Non-Independent Director (Age 63)
  • Andrew Bishop, Independent Director
  • Kenneth H. Galbraith, Independent Director (Age 54)

How do I buy ProMetic Life Sciences stock?

Shares of ProMetic Life Sciences and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of ProMetic Life Sciences stock can currently be purchased for approximately C$1.27.

How big of a company is ProMetic Life Sciences?

ProMetic Life Sciences has a market capitalization of C$886.76 million.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.


MarketBeat Community Rating for ProMetic Life Sciences (PLI)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ProMetic Life Sciences (TSE:PLI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.672.752.78
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$3.73C$3.81C$3.74C$4.72
Price Target Upside: 166.07% upside153.89% upside149.05% upside125.78% upside

ProMetic Life Sciences (TSE:PLI) Consensus Price Target History

Price Target History for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/20/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
11/15/2017National Bank FinancialLower Price TargetSector PerformC$2.50 -> C$2.00View Rating Details
8/16/2017Royal Bank Of CanadaLower Price TargetOutperformC$4.00 -> C$3.50View Rating Details
8/16/2017TD SecuritiesLower Price TargetSpeculative BuyC$4.50 -> C$3.50View Rating Details
7/7/2017ScotiabankLower Price TargetOutperformC$4.75 -> C$4.00View Rating Details
6/19/2017Canaccord GenuityLower Price TargetBuyC$4.75 -> C$4.50View Rating Details
10/13/2016Bloom BurtonReiterated RatingHoldView Rating Details
8/25/2016CIBCLower Price TargetC$5.00 -> C$4.85View Rating Details
3/28/2016Paradigm CapitalBoost Price TargetBuyC$2.90 -> C$3.30View Rating Details
1/29/2016Panmure GordonBoost Price TargetBuyC$6.70View Rating Details
(Data available from 12/11/2015 forward)

Earnings

Earnings History for ProMetic Life Sciences (TSE:PLI)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

ProMetic Life Sciences (TSE:PLI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ProMetic Life Sciences (TSE:PLI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ProMetic Life Sciences (TSE PLI) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE PLI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/6/2017Bruce WendelDirectorBuy625C$1.00C$625.00
10/18/2017Martin LeclercInsiderBuy10,000C$1.61C$16,100.00
10/6/2017Jonathan BoothInsiderBuy75,000C$1.21C$90,750.00
10/3/2017Bruce WendelDirectorBuy450C$1.28C$576.00
9/13/2017Pierre LaurinDirectorSell82,738C$1.44C$119,142.72
9/12/2017Pierre LaurinDirectorSell82,738C$1.45C$119,970.10
9/11/2017Bruce WendelDirectorBuy7,450C$1.21C$9,014.50
9/7/2017Pierre LaurinDirectorSell41,427C$1.45C$60,069.15
8/25/2017Bruce PritchardInsiderSell84,594C$1.15C$97,283.10
8/24/2017Dwun-Hou ChenDirectorSell32,321C$1.14C$36,845.94
8/24/2017Patrick SartoreInsiderSell64,579C$1.15C$74,265.85
8/22/2017Bruce PritchardInsiderBuy48,400C$1.30C$62,920.00
8/22/2017Simon Geoffrey BestDirectorBuy10,000C$1.29C$12,900.00
8/18/2017Louise MénardDirectorBuy6,400C$1.20C$7,680.00
8/18/2017Patrick SartoreInsiderBuy9,250C$1.21C$11,192.50
8/17/2017Nancy Orr-GaucherDirectorBuy17,200C$1.18C$20,296.00
7/10/2017Louise MénardDirectorSell82,202C$1.60C$131,523.20
6/1/2017Martin LeclercInsiderBuy7,000C$2.04C$14,280.00
5/30/2017Bruce WendelDirectorBuy2,474C$1.52C$3,760.48
5/25/2017Martin LeclercInsiderBuy8,950C$2.03C$18,168.50
5/18/2017Simon Geoffrey BestDirectorBuy10,000C$2.06C$20,600.00
4/19/2017Andrew Trevor BishopDirectorBuy10,000C$2.09C$20,900.00
4/7/2017Bruce PritchardInsiderBuy15,300C$2.18C$33,354.00
2/6/2017Bruce WendelDirectorBuy1,210C$1.66C$2,008.60
10/7/2016Simon Geoffrey BestDirectorBuy2,750C$2.93C$8,057.50
4/6/2016Bruce PritchardInsiderBuy8,800C$3.19C$28,050.88
4/5/2016Bruce WendelDirectorBuy35,200C$2.45C$86,387.84
1/21/2016Raymond Manuel HakimDirectorBuy10,000C$2.77C$27,700.00
1/20/2016Pierre LaurinDirectorBuy2,000C$2.62C$5,240.00
1/19/2016Gregory WeaverInsiderBuy25,000C$2.78C$69,500.00
1/12/2016Louise M�NardDirectorBuy1,867C$2.94C$5,488.98
12/31/2015Kurt Stefan Victor ClulowDirectorBuy273,800C$3.42C$937,737.62
12/29/2015Kurt Stefan Victor ClulowDirectorBuy232,700C$3.22C$749,875.75
12/21/2015Kurt Stefan Victor ClulowDirectorBuy439,500C$3.16C$1,388,160.75
12/4/2015Gregory WeaverInsiderBuy5,000C$2.14C$10,706.50
12/3/2015Gregory WeaverInsiderBuy5,000C$2.24C$11,184.00
12/3/2015Pierre LaurinDirectorSell259,125C$2.99C$774,913.31
11/17/2015Jonathan BoothInsiderBuy25,000C$2.21C$55,225.00
9/30/2015Kurt Stefan Victor ClulowDirectorBuy50,000C$1.43C$71,500.00
9/29/2015Kurt Stefan Victor ClulowDirectorBuy153,400C$1.42C$217,889.36
9/25/2015Raymond Manuel HakimDirectorBuy15,000C$1.69C$25,399.50
9/15/2015Andrew Trevor BishopDirectorBuy10,000C$1.81C$18,100.00
9/8/2015Simon Geoffrey BestDirectorBuy30,000C$1.95C$58,464.00
8/24/2015Nancy Orr-GaucherDirectorBuy2,800C$1.75C$4,900.00
8/21/2015Pierre LaurinDirectorBuy2,400C$1.83C$4,392.00
7/16/2015Simon Geoffrey BestDirectorBuy60,000C$2.43C$145,782.00
7/15/2015Patrick SartoreInsiderSell122,736C$2.30C$282,722.38
7/15/2015Steven J BurtonDirectorSell49,842C$2.30C$114,811.05
7/2/2015Kurt Stefan Victor ClulowDirectorBuy229,900C$2.32C$533,184.08
6/30/2015Kurt Stefan Victor ClulowDirectorBuy770,100C$2.26C$1,742,736.30
6/29/2015Kurt Stefan Victor ClulowDirectorBuy114,750C$2.10C$240,435.68
6/26/2015Kurt Stefan Victor ClulowDirectorBuy885,250C$2.12C$1,879,208.70
6/16/2015Patrick SartoreInsiderBuy2,300C$2.24C$5,152.00
6/12/2015Patrick SartoreInsiderBuy4,000C$2.28C$9,122.00
6/11/2015Louise M�NardDirectorBuy10,000C$2.35C$23,500.00
6/5/2015Raymond Manuel HakimDirectorBuy50,000C$2.45C$122,495.00
6/4/2015Paul MesburisDirectorSell115,593C$2.40C$277,423.20
5/22/2015Nancy Orr-GaucherDirectorSell9,787C$2.47C$24,173.89
4/9/2015Nancy Orr-GaucherDirectorSell9,657C$2.72C$26,267.04
4/7/2015Bruce PritchardInsiderBuy10,200C$2.74C$27,943.92
2/6/2015John Edward MoranDirectorBuy64,500C$1.51C$97,395.00
1/12/2015Patrick SartoreInsiderSell279,656C$1.87C$523,348.24
1/12/2015Pierre LaurinDirectorSell956,264C$1.87C$1,789,552.45
(Data available from 1/1/2013 forward)

Headlines

ProMetic Life Sciences (TSE PLI) News Headlines

Source:
DateHeadline
ProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of "Buy" by BrokeragesProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 8 at 5:42 PM
Pivotal Data for Prometics Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for ... - PR Newswire (press release)Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for ... - PR Newswire (press release)
www.prnewswire.com - December 8 at 10:21 AM
ETFs with exposure to ProMetic Life Sciences, Inc. : November 27, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:44 PM
ProMetic Life Sciences Inc. (PLI) Receives Overweight Rating from Cantor FitzgeraldProMetic Life Sciences Inc. (PLI) Receives Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - November 22 at 6:10 AM
ProMetic Life Sciences Inc. to Post FY2017 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (PLI)ProMetic Life Sciences Inc. to Post FY2017 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (PLI)
www.americanbankingnews.com - November 22 at 5:52 AM
FY2017 EPS Estimates for ProMetic Life Sciences Inc. Lifted by Hybridan Llp (PLI)FY2017 EPS Estimates for ProMetic Life Sciences Inc. Lifted by Hybridan Llp (PLI)
www.americanbankingnews.com - November 20 at 1:56 AM
FY2018 EPS Estimates for ProMetic Life Sciences Inc. Increased by National Bank Financial (PLI)FY2018 EPS Estimates for ProMetic Life Sciences Inc. Increased by National Bank Financial (PLI)
www.americanbankingnews.com - November 18 at 8:50 AM
ETFs with exposure to ProMetic Life Sciences, Inc. : November 17, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 2:08 PM
ProMetic Life Sciences And Other High Growth StocksProMetic Life Sciences And Other High Growth Stocks
finance.yahoo.com - November 16 at 9:39 AM
ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
finance.yahoo.com - November 16 at 9:39 AM
ProMetic Life Sciences Inc. (PLI) Given New C$2.00 Price Target at National Bank FinancialProMetic Life Sciences Inc. (PLI) Given New C$2.00 Price Target at National Bank Financial
www.americanbankingnews.com - November 15 at 3:00 PM
ProMetic Life Sciences Inc. 2017 Q3 - Results - Earnings Call SlidesProMetic Life Sciences Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 15 at 7:29 AM
Edited Transcript of PLI.TO earnings conference call or presentation 14-Nov-17 4:00pm GMTEdited Transcript of PLI.TO earnings conference call or presentation 14-Nov-17 4:00pm GMT
finance.yahoo.com - November 15 at 7:28 AM
ProMetic Life Sciences Inc. (PLI) Set to Announce Quarterly Earnings on MondayProMetic Life Sciences Inc. (PLI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - November 10 at 9:56 AM
BRIEF-Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trialBRIEF-Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial
www.reuters.com - November 2 at 7:44 AM
ETFs with exposure to ProMetic Life Sciences, Inc. : October 31, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : October 31, 2017
finance.yahoo.com - October 31 at 4:23 PM
ProMetic Life Sciences, Inc. breached its 50 day moving average in a Bearish Manner : PLI-CA : October 30, 2017ProMetic Life Sciences, Inc. breached its 50 day moving average in a Bearish Manner : PLI-CA : October 30, 2017
finance.yahoo.com - October 31 at 7:56 AM
ProMetic Life Sciences Inc. (PLI) Receives Average Rating of "Buy" from AnalystsProMetic Life Sciences Inc. (PLI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 19 at 4:32 PM
Martin Leclerc Buys 10,000 Shares of ProMetic Life Sciences Inc. (PLI) StockMartin Leclerc Buys 10,000 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - October 18 at 4:20 PM
FY2017 EPS Estimates for ProMetic Life Sciences Inc. Reduced by National Bank Financial (PLI)FY2017 EPS Estimates for ProMetic Life Sciences Inc. Reduced by National Bank Financial (PLI)
www.americanbankingnews.com - October 18 at 8:58 AM
Are These 3 Stocks About to Take Off?Are These 3 Stocks About to Take Off?
www.fool.ca - October 17 at 4:06 PM
Prometic Life Sciences Inc.Prometic Life Sciences Inc.
www.baystreet.ca - October 14 at 6:49 AM
BRIEF-FDA accepts Prometics Biologics License Application for PlasminogenBRIEF-FDA accepts Prometic's Biologics License Application for Plasminogen
www.reuters.com - October 13 at 8:07 AM
Insider Buying: ProMetic Life Sciences Inc. (PLI) Insider Purchases 75,000 Shares of StockInsider Buying: ProMetic Life Sciences Inc. (PLI) Insider Purchases 75,000 Shares of Stock
www.americanbankingnews.com - October 11 at 4:28 PM
What kind of year can investors expect in 2018?What kind of year can investors expect in 2018?
www.theglobeandmail.com - October 3 at 10:49 AM
BRIEF-Prometic receives FDA clearance of its IND to initiate PBI-4050 phase 2/3 trial in patients with idiopathic pulmonary fibrosisBRIEF-Prometic receives FDA clearance of its IND to initiate PBI-4050 phase 2/3 trial in patients with idiopathic pulmonary fibrosis
www.reuters.com - September 25 at 11:44 AM
ProMetic Life Sciences Inc. (PLI) Receives Consensus Recommendation of "Buy" from BrokeragesProMetic Life Sciences Inc. (PLI) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 24 at 2:46 PM
ProMetic Life Sciences, Inc. – Value Analysis (TORONTO:PLI) : September 22, 2017ProMetic Life Sciences, Inc. – Value Analysis (TORONTO:PLI) : September 22, 2017
finance.yahoo.com - September 22 at 1:18 PM
BRIEF-Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patientsBRIEF-Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patients
www.reuters.com - September 20 at 7:47 AM
Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients - PR Newswire (press release)Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients - PR Newswire (press release)
www.prnewswire.com - September 19 at 6:34 AM
Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients - PR Newswire (press release)Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients - PR Newswire (press release)
www.prnewswire.com - September 19 at 6:34 AM
Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome PatientsPrometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients
finance.yahoo.com - September 19 at 6:34 AM
Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome PatientsPrometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients
finance.yahoo.com - September 19 at 6:34 AM
Pierre Laurin Sells 82,738 Shares of ProMetic Life Sciences Inc. (PLI) StockPierre Laurin Sells 82,738 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - September 15 at 4:32 PM
ProMetic Life Sciences Inc. (PLI) Director Pierre Laurin Sells 82,738 SharesProMetic Life Sciences Inc. (PLI) Director Pierre Laurin Sells 82,738 Shares
www.americanbankingnews.com - September 15 at 4:32 PM
Insider Selling: ProMetic Life Sciences Inc. (PLI) Director Sells 41,427 Shares of StockInsider Selling: ProMetic Life Sciences Inc. (PLI) Director Sells 41,427 Shares of Stock
www.americanbankingnews.com - September 12 at 10:16 PM
ProMetic Life Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PLI-CA : August 31, 2017ProMetic Life Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PLI-CA : August 31, 2017
finance.yahoo.com - September 1 at 7:20 AM
Bruce Pritchard Sells 84,594 Shares of ProMetic Life Sciences Inc. (PLI) StockBruce Pritchard Sells 84,594 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - August 31 at 4:08 AM
ProMetic Life Sciences Inc. (PLI) Given Average Recommendation of "Buy" by AnalystsProMetic Life Sciences Inc. (PLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 30 at 2:32 PM
ProMetic Life Sciences Inc. (PLI) Price Target Raised to C$2.50 at National Bank FinancialProMetic Life Sciences Inc. (PLI) Price Target Raised to C$2.50 at National Bank Financial
www.americanbankingnews.com - August 30 at 1:50 PM
Prometic Stock Pops on FDA DesignationPrometic Stock Pops on FDA Designation
www.baystreet.ca - August 30 at 8:03 AM
ProMetic Life Sciences Inc. Jumps More Than 21% on FDA DesignationProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation
www.fool.ca - August 30 at 8:03 AM
ETFs with exposure to ProMetic Life Sciences, Inc. : August 30, 2017ETFs with exposure to ProMetic Life Sciences, Inc. : August 30, 2017
finance.yahoo.com - August 30 at 8:03 AM
Patrick Sartore Sells 64,579 Shares of ProMetic Life Sciences Inc. (PLI) StockPatrick Sartore Sells 64,579 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - August 29 at 10:34 PM
Dwun-Hou Chen Sells 32,321 Shares of ProMetic Life Sciences Inc. (PLI) StockDwun-Hou Chen Sells 32,321 Shares of ProMetic Life Sciences Inc. (PLI) Stock
www.americanbankingnews.com - August 25 at 8:52 PM
The Pharma Race: A New Treatment For Idiopathic Pulmonary FibrosisThe Pharma Race: A New Treatment For Idiopathic Pulmonary Fibrosis
seekingalpha.com - August 22 at 3:25 PM
ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017
finance.yahoo.com - August 22 at 3:25 PM
ProMetic Life Sciences Inc. (PLI) Insider Patrick Sartore Buys 9,250 SharesProMetic Life Sciences Inc. (PLI) Insider Patrick Sartore Buys 9,250 Shares
www.americanbankingnews.com - August 22 at 1:32 PM
ProMetic Life Sciences Inc. (PLI) Director Acquires C$12,900.00 in StockProMetic Life Sciences Inc. (PLI) Director Acquires C$12,900.00 in Stock
www.americanbankingnews.com - August 22 at 1:32 PM
ProMetic Life Sciences Inc. (PLI) Insider Bruce Pritchard Purchases 48,400 SharesProMetic Life Sciences Inc. (PLI) Insider Bruce Pritchard Purchases 48,400 Shares
www.americanbankingnews.com - August 22 at 1:32 PM

SEC Filings

ProMetic Life Sciences (TSE:PLI) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Financials are not available for this stock.

Chart

ProMetic Life Sciences (TSE PLI) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.